GOLDEN VALLEY, Minn.–(BUSINESS WIRE)–Preceptis Medical, Inc., a pioneer in pediatric ENT innovation, today announced the publication of a health economic study assessing the financial impact of shifting pediatric tympanostomy tube (ear tube) placement from operating room to in-office settings. The analysis, published in the Journal of Medical Economics, demonstrates significant cost savings potential for Commercial and Medicaid health insurance payers that provide access to in-office ear tube procedures utilizing the Hummingbird® Tympanostomy Tube System (TTS).
Key findings from the study include1:
Pediatric ear tube surgeries historically have been performed in the operating room (OR) under general anesthesia. However, the procedure can be safely and effectively performed in an office setting by using the Hummingbird® TTS, helping pediatric patients avoid risks associated with operating room surgeries and general anesthesia exposure2. This analysis demonstrates that in addition to the important clinical and safety benefits, Payers may also experience significant cost savings.
“Shifting ear tube placement into the office with the Hummingbird® Device has improved patient access and offered families an important alternative to OR-based surgeries,” said Dr. Gene Liu, Pediatric Otolaryngologist at Cedars-Sinai Medical Center. “This analysis demonstrates that payers can also realize meaningful cost savings, even when accounting for the additional resources required to treat children in-office. My hope is that these findings encourage payers to establish sustainable reimbursement rates that expand access to this safe and cost-effective option.”
To support patient access to pediatric in-office ear tube procedures with tympanostomy tube delivery devices, the Centers for Medicare & Medicaid Services (CMS) established add-on HCPCS Code (+G0561) in the 2025 Physician Fee Schedule3. CMS stated in the 2025 PFS, “These minimally invasive, in-office procedures can offer significant benefits, including reduced risks associated with general anesthesia, quicker recovery, fewer infections, and improved access to care.” The new add-on G code facilitates fair reimbursement to providers for the incremental work and practice expenses (including device costs) involved in performing pediatric ear tube procedures in-office. This is the first economic study to evaluate the economic impact of utilizing the add-on code +G0561.
“This study reinforces what we have seen in our Health System, where we have been offering in-office ear tube procedures with the Hummingbird Device since 2021,” shared Dr. Mark Gerber, Pediatric Otolaryngologist at Phoenix Children’s Hospital. “Providing a mechanism for reimbursement for the incremental costs of the pediatric procedure will remove a significant barrier to utilization and save healthcare dollars.”
About Preceptis Medical
Founded in 2011, Preceptis Medical is an innovative medical technology company dedicated to providing less invasive ear tube procedure options for pediatric patients. The FDA-cleared Hummingbird® Tympanostomy Tube System (TTS) streamlines ear tube placement, which enables the procedure to be performed with only a topical anesthetic. The Hummingbird, indicated for use in patients 6 months of age and older, provides a simple and efficient option for ENTs and parents while reducing healthcare costs. For more information, please visit https://www.hummingbirdeartubes.com/
References:
Contacts
Greg Mielke
Chief Commercial Officer
Preceptis Medical, Inc.
763.568.7810
Greg@preceptismedical.com
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…